Get the Stockscreener App
1.31
1.50%
-0.02
After Hours:
1.30
-0.01
-0.76%
Pacific Biosciences Of California Inc stock is traded at $1.31, with a volume of 3.26M.
It is down -1.50% in the last 24 hours and down -14.94% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.33
Open:
$1.34
24h Volume:
3.26M
Relative Volume:
0.38
Market Cap:
$393.49M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-0.8733
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
-5.07%
1M Performance:
-14.94%
6M Performance:
-10.27%
1Y Performance:
-3.68%
1-Day Range:
$1.30
$1.35
1-Week Range:
$1.29
$1.38
52-Week Range:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.31 | 399.49M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
132.66 | 228.64B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.50 | 156.70B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
391.41 | 148.97B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.81 | 117.96B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
81.34 | 47.69B | 5.69B | 1.41B | 577.90M | 6.95 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
What makes Pacific Biosciences of California Inc. stock price move sharplyPrice Action & Real-Time Volume Trigger Notifications - Newser
Is Pacific Biosciences of California Inc. stock bottoming outWeekly Investment Recap & Stock Timing and Entry Methods - Newser
Relative strength of Pacific Biosciences of California Inc. in sector analysisTrade Ideas & Risk Controlled Swing Trade Alerts - Newser
Will Pacific Biosciences of California Inc. benefit from macro trendsStop Loss & Weekly High Return Opportunities - Newser
Can momentum traders help lift Pacific Biosciences of California Inc.Day Trade & Weekly Market Pulse Updates - Newser
Real time pattern detection on Pacific Biosciences of California Inc. stockQuarterly Market Summary & Risk Managed Investment Strategies - Newser
What high frequency data says about Pacific Biosciences of California Inc.2025 Big Picture & Scalable Portfolio Growth Methods - Newser
Tick level data insight on Pacific Biosciences of California Inc. volatilityEarnings Overview Summary & AI Powered Buy/Sell Recommendations - Newser
Visual analytics tools that track Pacific Biosciences of California Inc. performanceJuly 2025 Catalysts & Scalable Portfolio Growth Ideas - Newser
Using Ichimoku Cloud for Pacific Biosciences of California Inc. technicals2025 Earnings Impact & Reliable Breakout Stock Forecasts - Newser
Volatility clustering patterns for Pacific Biosciences of California Inc.Market Activity Summary & Daily Stock Momentum Reports - Newser
Will a bounce in Pacific Biosciences of California Inc. offer an exitEarnings Miss & AI Forecast Swing Trade Picks - Newser
Is Pacific Biosciences of California Inc. reversing from oversold territoryMarket Trend Report & Reliable Price Breakout Alerts - Newser
Is Pacific Biosciences of California Inc. affected by consumer sentimentJuly 2025 Drop Watch & AI Powered Buy and Sell Recommendations - sundaytimes.kr
Published on: 2025-08-28 22:15:20 - Newser
Combining machine learning predictions for Pacific Biosciences of California Inc.Market Growth Report & Reliable Price Action Trade Plans - Newser
Should you hold or exit Pacific Biosciences of California Inc. nowMarket Movement Recap & Verified Technical Signals - Newser
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):